Otsuka Announces Positive Top-line Results from Two Phase 3 Studies of Centanafadine for the Treatment of Attention-deficit Hyperactivity Disorder (ADHD) in Adult Patients
Otsuka Pharmaceutical to Acquire Neurovance, Inc., a VIESF IV Portfolio Company
Neurovance Announces the Appointment of Brian Goff as Chief Operating Officer as the Company Prepares for the Next Stage of Growth and Development — Executive Board Chairman Jeff Bailey Becomes CEO
